Singular Genomics Systems, Inc.
NASDAQ:OMIC
19.8 (USD) • At close January 14, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0.406 | 0.737 | 0.442 | 1.081 | 0.462 | 0.505 | 0.863 | 0.765 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.707 | 0.915 | 2.583 | 1.538 | 0.527 | 0.597 | 0.807 | 0.789 | 1.667 | 1.542 | 0.461 | 0.364 | 0.303 | 0.255 | 0.211 | 0 | 0 | 0 | 0 |
| Gross Profit
| -0.301 | -0.178 | -2.141 | -0.457 | -0.065 | -0.092 | 0.056 | -0.024 | -1.667 | -1.542 | -0.461 | -0.364 | -0.303 | -0.255 | -0.211 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| -0.741 | -0.242 | -4.844 | -0.423 | -0.141 | -0.182 | 0.065 | -0.031 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 9.568 | 10.728 | 11.494 | 11.69 | 11.22 | 12.624 | 12.23 | 10.76 | 12.732 | 12.061 | 10.645 | 9.455 | 8.91 | 7.682 | 6.608 | 5.816 | 6.08 | 5.325 | 4.026 |
| General & Administrative Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 23.557 | 0 | 12.182 | 11.375 | 18.406 | 8.551 | 6.201 | 3.654 | 1.769 | 1.698 | 1.443 | 1.377 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | -11.811 | 0 | 0 | 0 | -8.188 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 8.202 | 11.898 | 13.213 | 13.134 | 13.254 | 14.887 | 13.204 | 11.746 | 11.962 | 12.182 | 11.375 | 10.218 | 8.551 | 6.201 | 3.654 | 1.769 | 1.698 | 1.443 | 1.377 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.001 | -0.007 | -23.799 | -11.4 | 0 | 0.02 | 0 | 0 |
| Operating Expenses
| 17.77 | 22.626 | 24.707 | 24.824 | 24.474 | 27.511 | 25.434 | 22.506 | 24.694 | 24.243 | 22.02 | 19.673 | 17.461 | 13.883 | 10.262 | 7.585 | 7.778 | 6.768 | 5.403 |
| Operating Income
| -18.071 | -22.804 | -26.848 | -25.281 | -24.539 | -27.603 | -25.378 | -22.53 | -24.694 | -24.243 | -22.02 | -19.673 | -17.461 | -13.883 | -10.262 | -7.585 | -7.778 | -6.768 | -5.403 |
| Operating Income Ratio
| -44.51 | -30.942 | -60.742 | -23.387 | -53.115 | -54.659 | -29.407 | -29.451 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 1.276 | 1.55 | 1.824 | 2.032 | 2.179 | 2.025 | 1.745 | 1.429 | 0.904 | 0.261 | 0.014 | -0.087 | -0.15 | -23.596 | -13.659 | -0.327 | -0.155 | -0.079 | 0.15 |
| Income Before Tax
| -16.795 | -21.254 | -25.024 | -23.249 | -22.36 | -25.578 | -23.633 | -21.101 | -23.79 | -23.982 | -22.006 | -19.759 | -17.611 | -37.479 | -23.921 | -7.912 | -7.933 | -6.847 | -5.253 |
| Income Before Tax Ratio
| -41.367 | -28.839 | -56.615 | -21.507 | -48.398 | -50.65 | -27.385 | -27.583 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | 1.679 | 2.319 | 2.464 | 2.295 | -1.486 | -1.429 | -0.904 | -0.261 | -0.014 | -0.364 | 0.15 | 23.596 | 13.602 | 0.327 | 0.155 | 0.079 | -0.15 |
| Net Income
| -16.795 | -21.254 | -25.024 | -23.249 | -22.36 | -25.578 | -22.147 | -19.672 | -22.886 | -23.721 | -21.992 | -19.759 | -17.611 | -37.479 | -23.921 | -7.912 | -7.933 | -6.847 | -5.253 |
| Net Income Ratio
| -41.367 | -28.839 | -56.615 | -21.507 | -48.398 | -50.65 | -25.663 | -25.715 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -6.72 | -8.57 | -10.16 | -9.48 | -9.17 | -10.58 | -9.24 | -8.24 | -9.64 | -10.05 | -9.29 | -8.21 | -7.37 | -35.55 | -10.55 | -3.42 | -3.43 | -2.96 | -2.27 |
| EPS Diluted
| -6.72 | -8.57 | -10.16 | -9.48 | -9.17 | -10.58 | -9.24 | -8.24 | -9.64 | -10.05 | -9.29 | -8.21 | -7.37 | -35.55 | -10.55 | -3.42 | -3.43 | -2.96 | -2.27 |
| EBITDA
| -14.818 | -19.188 | -23.018 | -21.308 | -20.205 | -23.426 | -21.557 | -19.137 | -21.912 | -22.273 | -21.403 | -19.203 | -17.074 | -36.992 | -23.522 | -7.499 | -7.56 | -6.473 | -5.056 |
| EBITDA Ratio
| -36.498 | -26.035 | -56.846 | -19.711 | -43.734 | -46.388 | -24.979 | -27.265 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |